SOUTH SAN FRANCISCO, Calif., Dec. 1, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (NasdaqCM:HNAB - News), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that several presentations related to the Company's lead anti-cancer compound, Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)), will be presented at the upcoming annual meeting of the American Society of Hematology (ASH) in San Francisco during December 6-9, 2008.
